Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195936 · ClinicalTrials.gov registry record · Phase 1
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
A Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00195936: Completed Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Children's Mercy Hospital Kansas City.
NCT00195936 is a Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195936, a Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.
Conditions Studied
Interventions
- DRUG Cinacalcet
Study Locations (1)
Missouri
- Section of Pediatric Nephrology, Children's Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
What the finished NCT00195936 record still lists
NCT00195936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Hypophosphatemic Rickets, X-Linked Dominant appearing as the primary indexed condition, and to 1 intervention - of which Cinacalcet is the first listed.
NCT00195936 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00195936 about?
NCT00195936 is a clinical study titled "Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets". This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of ...
What is the current status of trial NCT00195936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-06. Estimated completion is 2008-02.
What conditions does trial NCT00195936 study?
This clinical trial studies the following conditions: Hypophosphatemic Rickets, X-Linked Dominant.
What interventions are being tested in trial NCT00195936?
The interventions under investigation include: Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT00195936?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195936 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatemic Rickets, X-Linked Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00195936's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia